Overview

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG.
Phase:
Phase 3
Details
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.
Treatments:
3,4-diaminopyridine
4-Aminopyridine
Amifampridine